Pulmonx Corp (LUNG) - Net Assets
Based on the latest financial reports, Pulmonx Corp (LUNG) has net assets worth $39.20 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($114.73 Million) and total liabilities ($75.54 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Pulmonx Corp (LUNG) strategic asset index to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $39.20 Million |
| % of Total Assets | 34.16% |
| Annual Growth Rate | N/A |
| 5-Year Change | -72.0% |
| 10-Year Change | N/A |
| Growth Volatility | 7.51 |
Pulmonx Corp - Net Assets Trend (2013–2025)
This chart illustrates how Pulmonx Corp's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Pulmonx Corp market cap and net worth.
Annual Net Assets for Pulmonx Corp (2013–2025)
The table below shows the annual net assets of Pulmonx Corp from 2013 to 2025. Also explore Pulmonx Corp annual equity growth to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $54.12 Million | -36.93% |
| 2024-12-31 | $85.81 Million | -27.47% |
| 2023-12-31 | $118.31 Million | -23.18% |
| 2022-12-31 | $154.01 Million | -20.30% |
| 2021-12-31 | $193.24 Million | -14.55% |
| 2020-12-31 | $226.13 Million | +220.68% |
| 2019-12-31 | $-187.38 Million | -11.98% |
| 2018-12-31 | $-167.33 Million | -264756.91% |
| 2017-12-31 | $-63.18K | +97.77% |
| 2016-12-31 | $-2.84 Million | -6.92% |
| 2015-12-31 | $-2.65 Million | -87.51% |
| 2014-12-31 | $-1.41 Million | +20.38% |
| 2013-12-31 | $-1.78 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Pulmonx Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 51297176500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $42.00K | 0.08% |
| Other Comprehensive Income | $2.36 Million | 4.36% |
| Other Components | $573.27 Million | 1059.34% |
| Total Equity | $54.12 Million | 100.00% |
Pulmonx Corp Competitors by Market Cap
The table below lists competitors of Pulmonx Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
C-Media Electronics
TWO:6237
|
$85.06 Million |
|
Chemcon Speciality Chemicals Limited
NSE:CHEMCON
|
$85.08 Million |
|
Zeder Investments Ltd
JSE:ZED
|
$85.10 Million |
|
Maywood Acquisition Corp. Unit
NASDAQ:MAYAU
|
$85.11 Million |
|
Jinro Distillers Co. Ltd
KQ:018120
|
$85.03 Million |
|
Precot Limited
NSE:PRECOT
|
$85.02 Million |
|
Passus S.A.
WAR:PAS
|
$84.97 Million |
|
Hwa Fong Rubber (Thailand) Public Company Limited
BK:HFT
|
$84.96 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pulmonx Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 85,809,000 to 54,116,000, a change of -31,693,000 (-36.9%).
- Net loss of 54,003,000 reduced equity.
- Other comprehensive income increased equity by 247,000.
- Other factors increased equity by 22,063,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-54.00 Million | -99.79% |
| Other Comprehensive Income | $247.00K | +0.46% |
| Other Changes | $22.06 Million | +40.77% |
| Total Change | $- | -36.93% |
Book Value vs Market Value Analysis
This analysis compares Pulmonx Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.49x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-8.08 | $1.98 | x |
| 2019-12-31 | $-5.29 | $1.98 | x |
| 2020-12-31 | $6.34 | $1.98 | x |
| 2021-12-31 | $5.35 | $1.98 | x |
| 2022-12-31 | $4.15 | $1.98 | x |
| 2023-12-31 | $3.12 | $1.98 | x |
| 2024-12-31 | $2.19 | $1.98 | x |
| 2025-12-31 | $1.33 | $1.98 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pulmonx Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -99.79%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -59.67%
- • Asset Turnover: 0.70x
- • Equity Multiplier: 2.39x
- Recent ROE (-99.79%) is below the historical average (-22.66%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 0.00% | -1072.14% | 1.10x | 0.00x | $-1.06 Million |
| 2014 | 0.00% | -579.35% | 0.70x | 0.00x | $-1.78 Million |
| 2015 | 0.00% | -14398.30% | 0.02x | 0.00x | $-2.54 Million |
| 2016 | 0.00% | -31539.27% | 0.02x | 0.00x | $-2.49 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.36 Million |
| 2018 | 0.00% | -92.38% | 1.33x | 0.00x | $-1.75 Million |
| 2019 | 0.00% | -63.52% | 0.61x | 0.00x | $-1.97 Million |
| 2020 | -14.25% | -98.47% | 0.12x | 1.17x | $-54.84 Million |
| 2021 | -25.18% | -100.51% | 0.21x | 1.22x | $-67.98 Million |
| 2022 | -38.26% | -109.80% | 0.28x | 1.26x | $-74.32 Million |
| 2023 | -51.42% | -88.60% | 0.39x | 1.50x | $-72.67 Million |
| 2024 | -65.72% | -67.30% | 0.51x | 1.90x | $-64.97 Million |
| 2025 | -99.79% | -59.67% | 0.70x | 2.39x | $-59.41 Million |
Industry Comparison
This section compares Pulmonx Corp's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $638,670,729
- Average return on equity (ROE) among peers: -85.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pulmonx Corp (LUNG) | $39.20 Million | 0.00% | 1.93x | $85.04 Million |
| Abbott Laboratories (ABT) | $4.40 Billion | 38.41% | 1.14x | $177.76 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $12.40 Million | -202.26% | 2.49x | $11.55 Million |
| Aethlon Medical Inc (AEMD) | $-9.30 Million | 0.00% | 0.00x | $1.11 Million |
| Acutus Medical Inc (AFIB) | $-131.82 Million | 0.00% | 0.00x | $903.35K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $780.04 Million |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $1.53 Million | -361.86% | 1.36x | $4.88 Million |
| Allurion Technologies, Inc. (ALUR) | $-32.31 Million | 0.00% | 0.00x | $1.19 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $644.00K | -309.01% | 0.34x | $4.16 Million |
| Artivion Inc (AORT) | $79.80 Million | -34.79% | 0.33x | $1.16 Billion |
| Apyx Medical Inc (APYX) | $2.22 Million | 4.46% | 0.72x | $127.64 Million |
About Pulmonx Corp
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ven… Read more